Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation.
In response to DNA damage, the ATM protein kinase activates signal transduction pathways essential for coordinating cell cycle progression with DNA repair. In the human disease ataxia-telangiectasia, mutation of the ATM gene results in multiple cellular defects, including enhanced sensitivity to ionizing radiation (IR). This phenotype highlights ATM as a potential target for novel inhibitors that could be used to enhance tumor cell sensitivity to radiotherapy. A targeted compound library was screened for potential inhibitors of the ATM kinase, and CP466722 was identified. The compound is nontoxic and does not inhibit phosphatidylinositol 3-kinase (PI3K) or PI3K-like protein kinase family members in cells. CP466722 inhibited cellular ATM-dependent phosphorylation events and disruption of ATM function resulted in characteristic cell cycle checkpoint defects. Inhibition of cellular ATM kinase activity was rapidly and completely reversed by removing CP466722. Interestingly, clonogenic survival assays showed that transient inhibition of ATM is sufficient to sensitize cells to IR and suggests that therapeutic radiosensitization may only require ATM inhibition for short periods of time. The ability of CP466722 to rapidly and reversibly regulate ATM activity provides a new tool to ask questions about ATM function that could not easily be addressed using genetic models or RNA interference technologies.
Rainey
Michael D
MD
Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Charlton
Maura E
ME
Stanton
Robert V
RV
Kastan
Michael B
MB
D000818:Animals; D064007:Ataxia Telangiectasia Mutated Proteins; D002453:Cell Cycle / Q000187:drug effects; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors*; D004249:DNA Damage; D004273:DNA, Neoplasm / Q000528:radiation effects*; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors*; D006367:HeLa Cells; D006801:Humans; D007259:Infrared Rays; D051379:Mice; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D016315:Proto-Oncogene Proteins c-abl / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000494:pharmacology; D011836:Radiation Tolerance / Q000187:drug effects / Q000502:physiology*; D015398:Signal Transduction; D014230:Triazoles / Q000494:pharmacology; D025521:Tumor Suppressor Proteins / Q000037:antagonists & inhibitors*
C532253:2-(6,7-dimethoxyquinazolin-4-yl)-5-(pyridiin-2-yl)-2H-1,2,4-triazol-3-amine; D018797:Cell Cycle Proteins; D004273:DNA, Neoplasm; D004268:DNA-Binding Proteins; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D014230:Triazoles; D025521:Tumor Suppressor Proteins; D016315:Proto-Oncogene Proteins c-abl; C576324:ATM protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; C576325:Atm protein, mouse; D017346:Protein Serine-Threonine Kinases
J Clin Oncol. 2006 Aug 10;24(23):3799-808
16896009
Nat Rev Mol Cell Biol. 2000 Dec;1(3):179-86
11252893
Mutat Res. 2003 Nov 27;532(1-2):205-13
14643437
Am J Hum Genet. 1999 May;64(5):1264-9
10205255
Mol Cell Biol. 2002 Feb;22(4):1049-59
11809797
Nature. 2001 Jun 21;411(6840):969-74
11418864
Cancer Cell. 2008 May;13(5):379-80
18455120
Genes Dev. 2002 Mar 1;16(5):560-70
11877376
Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10389-94
10973490
Gene Ther. 2000 May;7(10):852-8
10845723
Genes Dev. 2001 May 1;15(9):1067-77
11331603
Cancer Res. 2004 Dec 15;64(24):9152-9
15604286
Nat Cell Biol. 2007 Jun;9(6):683-90
17486112
J Biol Chem. 1999 Dec 31;274(53):37538-43
10608806
Blood. 2005 Apr 1;105(7):2640-53
15618470
Cancer Res. 2004 Jun 1;64(11):3748-52
15172978
Nature. 2004 Nov 18;432(7015):316-23
15549093
Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16870-5
17077147
Cancer Res. 1996 Aug 1;56(15):3589-96
8758931
Semin Radiat Oncol. 2006 Jan;16(1):51-8
16378907
Semin Radiat Oncol. 2001 Oct;11(4):316-27
11677656
Science. 1998 Sep 11;281(5383):1677-9
9733515
Nature. 2003 Jan 30;421(6922):499-506
12556884
J Biol Chem. 2000 Nov 10;275(45):35631-7
10964922
Blood. 2003 Jan 15;101(2):664-72
12393636
Genes Dev. 2004 Jun 15;18(12):1423-38
15175241
Science. 1998 Sep 11;281(5383):1674-7
9733514
Oncogene. 2008 Feb 7;27(7):896-906
17684483
Nature. 2000 Nov 23;408(6811):429-32
11100717
Oncogene. 2001 Jan 18;20(3):278-88
11313956
Biochem Biophys Res Commun. 2005 May 27;331(1):1-14
15845350
Science. 1995 Jun 23;268(5218):1749-53
7792600
Trends Biochem Sci. 2006 Jul;31(7):402-10
16774833
Leuk Res. 2008 Apr;32(4):643-9
17900686
Genes Dev. 2007 Sep 15;21(18):2283-7
17761812
J Biol Chem. 2001 Aug 10;276(32):30537-41
11390408
J Cell Biochem. 2004 Feb 1;91(2):223-31
14743382
N Engl J Med. 1995 Sep 7;333(10):662-3
7637733
Cell. 2004 Jul 9;118(1):9-17
15242640
Nat Rev Cancer. 2003 Mar;3(3):155-68
12612651
DNA Repair (Amst). 2006 May 10;5(5):534-43
16531125
Annu Rev Genet. 1997;31:635-62
9442910
Nat Rev Cancer. 2004 Jun;4(6):470-80
15170449
Nature. 2000 Apr 6;404(6778):613-7
10766245
Cancer Res. 1999 May 15;59(10):2464-9
10344759
Cancer Gene Ther. 2000 Oct;7(10):1307-14
11059687
Cell. 2002 May 17;109(4):459-72
12086603
Cancer Res. 1994 Oct 1;54(19):5054-8
7923116
Cancer Res. 2003 Apr 1;63(7):1550-4
12670903
Cancer Res. 2002 Aug 15;62(16):4588-91
12183412